Drug intelligence / Profile preview

ANS06

Development stage: Preclinical
Lead developer: Avistone Biotechnology
Modality: Small Molecules

Overview

ANS06 is a preclinical-stage small molecule pan-RAS inhibitor being developed by Avistone Pharmaceutical for the treatment of solid tumors. The compound is designed to target multiple oncogenic RAS isoforms, which are common drivers of oncogenesis in various solid malignancies. By inhibiting RAS signaling, ANS06 aims to block the activation of downstream pathways such as MAPK/ERK and PI3K/AKT that promote tumor cell proliferation and survival. It is currently undergoing preclinical evaluation to support future clinical development, with global rights held by the developer.

Targets

HRAS (H-Ras protein)

Beyond the preview

Go deeper on ANS06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANS06.

Explore the full profile